| 2.23 0.03 (1.36%) | 09-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.72 | 1-year : | 3 |
| Resists | First : | 2.33 | Second : | 2.56 |
| Pivot price | 2.21 |
|||
| Supports | First : | 1.96 | Second : | 1.63 |
| MAs | MA(5) : | 2.21 |
MA(20) : | 2.17 |
| MA(100) : | 2.21 |
MA(250) : | 2.22  |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 38.5 |
D(3) : | 37.9 |
| RSI | RSI(14): 52.7 |
|||
| 52-week | High : | 9.78 | Low : | 0.96 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ PHIO ] has closed below upper band by 46.0%. Bollinger Bands are 23.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.26 - 2.27 | 2.27 - 2.28 |
| Low: | 2.14 - 2.15 | 2.15 - 2.16 |
| Close: | 2.21 - 2.23 | 2.23 - 2.25 |
Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT); PH-894 that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression for use in ACT; and PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for use in ACT. It has collaborations with AgonOx Inc. on clinical development of novel T cell-based cancer immunotherapies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.
Fri, 26 Sep 2025
Phio Pharmaceuticals Stockholders Approve Key 2025 Proposals - MSN
Tue, 23 Sep 2025
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series - Newsfile
Tue, 23 Sep 2025
Biotech Breakthrough: Phio's INTASYL Cancer Treatment Shows Positive Results in Skin Cancer Trial - Stock Titan
Thu, 18 Sep 2025
Phio Pharmaceuticals to Present at the Life Sciences Future Conference - FinancialContent
Thu, 18 Sep 2025
Clinical-Stage Biotech Phio Pharmaceuticals to Share INTASYL siRNA Cancer Trial Progress at Major Conference - Stock Titan
Thu, 14 Aug 2025
Phio Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update - Newsfile
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 6 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 7.5 (%) |
| Held by Institutions | 10.2 (%) |
| Shares Short | 290 (K) |
| Shares Short P.Month | 715 (K) |
| EPS | -2.09 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.09 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -56.1 % |
| Return on Equity (ttm) | -102.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.63 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.3 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -7 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -1.07 |
| PEG Ratio | 0 |
| Price to Book value | 1.06 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.79 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|